APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neuroleptics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Neuroleptics Market Outlook and Growth Opportunities 2026

21 December 2025197 pages

Choose your research edition.

Industry ResearchNeuroleptics Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Neuroleptics Industry Growth and Trends Forecast to 203296 pages · $3,450 USDMarket StructureGlobal Neuroleptics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neuroleptics Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Neuroleptics Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Neuroleptics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Neuroleptics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neuroleptics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neuroleptics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Neuroleptics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Neuroleptics market include Johnson & Johnson, Eli Lilly, Pfizer, GSK, Bristol-Myers Squibb, AstraZeneca and Allergan, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Neuroleptics market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neuroleptics and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neuroleptics sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Neuroleptics market size, projected growth trends, production technologies, key applications, and end-use industries.

Neuroleptics Segment by Company

Johnson & Johnson

Eli Lilly

Pfizer

GSK

Bristol-Myers Squibb

AstraZeneca

Allergan

Neuroleptics Segment by Type

First Generation

Second Generation

Third Generation

Neuroleptics Segment by Application

Bipolar Disorder

Schizophrenia

Unipolar Depression

Dementia

Others

Neuroleptics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Neuroleptics status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Neuroleptics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Neuroleptics significant trends, drivers, influence factors in global and regions.

6. To analyze Neuroleptics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuroleptics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neuroleptics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuroleptics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Neuroleptics market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neuroleptics industry.

Chapter 3: Detailed analysis of Neuroleptics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Neuroleptics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Neuroleptics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Neuroleptics Industry Trends Table 2. Neuroleptics Industry Drivers Table 3. Neuroleptics Industry Opportunities and Challenges Table 4. Neuroleptics Industry Restraints Table 5. Global Neuroleptics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Neuroleptics Revenue Share by Company (2021-2026) Table 7. Global Neuroleptics Sales Volume by Company (k tons) & (2021-2026) Table 8. Global Neuroleptics Sales Volume Share by Company (2021-2026) Table 9. Global Neuroleptics Average Price (US$/ton) of Company (2021-2026) Table 10. Global Neuroleptics Company Ranking, (2024-2026) & (USD Million) Table 11. Global Neuroleptics Key Company Manufacturing Base & Headquarters Table 12. Global Neuroleptics Company, Product Type & Application Table 13. Global Neuroleptics Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Neuroleptics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of First Generation Table 18. Significant Companies of Second Generation Table 19. Significant Companies of Third Generation Table 20. Global Neuroleptics Sales Volume by Type 2021 VS 2025 VS 2032 (k tons) Table 21. Global Neuroleptics Sales Volume by Type (2021-2026) & (k tons) Table 22. Global Neuroleptics Sales Volume by Type (2027-2032) & (k tons) Table 23. Global Neuroleptics Sales Volume Share by Type (2021-2026) Table 24. Global Neuroleptics Sales Volume Share by Type (2027-2032) Table 25. Global Neuroleptics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Neuroleptics Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Neuroleptics Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Neuroleptics Sales Value Share by Type (2021-2026) Table 29. Global Neuroleptics Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Bipolar Disorder Table 31. Significant Companies of Schizophrenia Table 32. Significant Companies of Unipolar Depression Table 33. Significant Companies of Dementia Table 34. Significant Companies of Others Table 35. Global Neuroleptics Sales Volume by Application 2021 VS 2025 VS 2032 (k tons) Table 36. Global Neuroleptics Sales Volume by Application (2021-2026) & (k tons) Table 37. Global Neuroleptics Sales Volume by Application (2027-2032) & (k tons) Table 38. Global Neuroleptics Sales Volume Share by Application (2021-2026) Table 39. Global Neuroleptics Sales Volume Share by Application (2027-2032) Table 40. Global Neuroleptics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Neuroleptics Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Neuroleptics Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Neuroleptics Sales Value Share by Application (2021-2026) Table 44. Global Neuroleptics Sales Value Share by Application (2027-2032) Table 45. Global Neuroleptics Sales by Region: 2021 VS 2025 VS 2032 (k tons) Table 46. Global Neuroleptics Sales by Region (2021-2026) & (k tons) Table 47. Global Neuroleptics Sales Market Share by Region (2021-2026) Table 48. Global Neuroleptics Sales by Region (2027-2032) & (k tons) Table 49. Global Neuroleptics Sales Market Share by Region (2027-2032) Table 50. Global Neuroleptics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Neuroleptics Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Neuroleptics Sales Value Share by Region (2021-2026) Table 53. Global Neuroleptics Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Neuroleptics Sales Value Share by Region (2027-2032) Table 55. Global Neuroleptics Market Average Price (US$/ton) by Region (2021-2026) Table 56. Global Neuroleptics Market Average Price (US$/ton) by Region (2027-2032) Table 57. Global Neuroleptics Sales by Country: 2021 VS 2025 VS 2032 (k tons) Table 58. Global Neuroleptics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Neuroleptics Sales by Country (2021-2026) & (k tons) Table 60. Global Neuroleptics Sales Market Share by Country (2021-2026) Table 61. Global Neuroleptics Sales by Country (2027-2032) & (k tons) Table 62. Global Neuroleptics Sales Market Share by Country (2027-2032) Table 63. Global Neuroleptics Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Neuroleptics Sales Value Market Share by Country (2021-2026) Table 65. Global Neuroleptics Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Neuroleptics Sales Value Market Share by Country (2027-2032) Table 67. Johnson & Johnson Company Information Table 68. Johnson & Johnson Business Overview Table 69. Johnson & Johnson Neuroleptics Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 70. Johnson & Johnson Neuroleptics Product Portfolio Table 71. Johnson & Johnson Recent Development Table 72. Eli Lilly Company Information Table 73. Eli Lilly Business Overview Table 74. Eli Lilly Neuroleptics Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 75. Eli Lilly Neuroleptics Product Portfolio Table 76. Eli Lilly Recent Development Table 77. Pfizer Company Information Table 78. Pfizer Business Overview Table 79. Pfizer Neuroleptics Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 80. Pfizer Neuroleptics Product Portfolio Table 81. Pfizer Recent Development Table 82. GSK Company Information Table 83. GSK Business Overview Table 84. GSK Neuroleptics Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 85. GSK Neuroleptics Product Portfolio Table 86. GSK Recent Development Table 87. Bristol-Myers Squibb Company Information Table 88. Bristol-Myers Squibb Business Overview Table 89. Bristol-Myers Squibb Neuroleptics Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 90. Bristol-Myers Squibb Neuroleptics Product Portfolio Table 91. Bristol-Myers Squibb Recent Development Table 92. AstraZeneca Company Information Table 93. AstraZeneca Business Overview Table 94. AstraZeneca Neuroleptics Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 95. AstraZeneca Neuroleptics Product Portfolio Table 96. AstraZeneca Recent Development Table 97. Allergan Company Information Table 98. Allergan Business Overview Table 99. Allergan Neuroleptics Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 100. Allergan Neuroleptics Product Portfolio Table 101. Allergan Recent Development Table 102. Key Raw Materials Table 103. Raw Materials Key Suppliers Table 104. Neuroleptics Distributors List Table 105. Neuroleptics Customers List Table 106. Research Programs/Design for This Report Table 107. Authors List of This Report Table 108. Secondary Sources Table 109. Primary Sources List of Figures Figure 1. Neuroleptics Product Image Figure 2. Global Neuroleptics Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neuroleptics Sales Value (2021-2032) & (US$ Million) Figure 4. Global Neuroleptics Sales (2021-2032) & (k tons) Figure 5. Global Neuroleptics Sales Average Price (US$/ton) & (2021-2032) Figure 6. Global Neuroleptics Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. First Generation Image Figure 10. Second Generation Image Figure 11. Third Generation Image Figure 12. Global Neuroleptics Sales Volume by Type (2021 VS 2025 VS 2032) & (k tons) Figure 13. Global Neuroleptics Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Neuroleptics Sales Volume Share by Type (2021-2032) Figure 15. Global Neuroleptics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Neuroleptics Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Neuroleptics Sales Value Share by Type (2021-2032) Figure 18. Bipolar Disorder Image Figure 19. Schizophrenia Image Figure 20. Unipolar Depression Image Figure 21. Dementia Image Figure 22. Others Image Figure 23. Global Neuroleptics Sales Volume by Application (2021 VS 2025 VS 2032) & (k tons) Figure 24. Global Neuroleptics Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Neuroleptics Sales Volume Share by Application (2021-2032) Figure 26. Global Neuroleptics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Neuroleptics Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Neuroleptics Sales Value Share by Application (2021-2032) Figure 29. Global Neuroleptics Sales by Region: 2021 VS 2025 VS 2032 (k tons) Figure 30. Global Neuroleptics Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Neuroleptics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Neuroleptics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Neuroleptics Sales Value (2021-2032) & (US$ Million) Figure 34. North America Neuroleptics Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Neuroleptics Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Neuroleptics Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Neuroleptics Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Neuroleptics Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Neuroleptics Sales Value (2021-2032) & (US$ Million) Figure 40. South America Neuroleptics Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Neuroleptics Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Neuroleptics Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Neuroleptics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Neuroleptics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Neuroleptics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Neuroleptics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Neuroleptics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Neuroleptics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Neuroleptics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Neuroleptics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Neuroleptics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Neuroleptics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Neuroleptics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Neuroleptics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Neuroleptics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Neuroleptics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Neuroleptics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Neuroleptics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Neuroleptics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Neuroleptics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Neuroleptics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Neuroleptics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Neuroleptics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Neuroleptics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Neuroleptics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Neuroleptics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Neuroleptics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Neuroleptics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Neuroleptics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Neuroleptics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Neuroleptics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Neuroleptics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Neuroleptics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Neuroleptics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Neuroleptics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Neuroleptics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Neuroleptics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Neuroleptics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Neuroleptics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Neuroleptics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Neuroleptics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Neuroleptics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Neuroleptics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Neuroleptics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Neuroleptics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Neuroleptics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Neuroleptics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Neuroleptics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Neuroleptics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Neuroleptics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Neuroleptics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Neuroleptics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Neuroleptics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Neuroleptics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Neuroleptics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Neuroleptics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Neuroleptics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Neuroleptics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Neuroleptics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Neuroleptics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Neuroleptics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Neuroleptics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Neuroleptics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Neuroleptics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Neuroleptics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Neuroleptics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Neuroleptics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Neuroleptics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Neuroleptics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Neuroleptics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Neuroleptics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Neuroleptics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Neuroleptics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Neuroleptics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Neuroleptics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Neuroleptics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Neuroleptics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Neuroleptics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Neuroleptics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Neuroleptics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Neuroleptics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Neuroleptics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Neuroleptics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Neuroleptics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Neuroleptics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Neuroleptics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Neuroleptics Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Neuroleptics Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • First Generation
  • Second Generation
  • Third Generation
Applications
  • Bipolar Disorder
  • Schizophrenia
  • Unipolar Depression
  • Dementia
  • Others
Companies covered
  • Johnson & Johnson
  • Eli Lilly
  • Pfizer
  • GSK
  • Bristol-Myers Squibb
  • AstraZeneca
  • Allergan

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Neuroleptics Sales Value (2021-2032)
  4. 1.2.2 Global Neuroleptics Sales Volume (2021-2032)
  5. 1.2.3 Global Neuroleptics Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Neuroleptics Market Dynamics
  1. 2.1 Neuroleptics Industry Trends
  2. 2.2 Neuroleptics Industry Drivers
  3. 2.3 Neuroleptics Industry Opportunities and Challenges
  4. 2.4 Neuroleptics Industry Restraints
3 Neuroleptics Market by Company
  1. 3.1 Global Neuroleptics Company Revenue Ranking in 2025
  2. 3.2 Global Neuroleptics Revenue by Company (2021-2026)
  3. 3.3 Global Neuroleptics Sales Volume by Company (2021-2026)
  4. 3.4 Global Neuroleptics Average Price by Company (2021-2026)
  5. 3.5 Global Neuroleptics Company Ranking (2024-2026)
  6. 3.6 Global Neuroleptics Company Manufacturing Base and Headquarters
  7. 3.7 Global Neuroleptics Company Product Type and Application
  8. 3.8 Global Neuroleptics Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Neuroleptics Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Neuroleptics Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Neuroleptics Market by Type
  1. 4.1 Neuroleptics Type Introduction
  2. 4.1.1 First Generation
  3. 4.1.2 Second Generation
  4. 4.1.3 Third Generation
  5. 4.2 Global Neuroleptics Sales Volume by Type
  6. 4.2.1 Global Neuroleptics Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Neuroleptics Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Neuroleptics Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Neuroleptics Sales Value by Type
  10. 4.3.1 Global Neuroleptics Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Neuroleptics Sales Value by Type (2021-2032)
  12. 4.3.3 Global Neuroleptics Sales Value Share by Type (2021-2032)
5 Neuroleptics Market by Application
  1. 5.1 Neuroleptics Application Introduction
  2. 5.1.1 Bipolar Disorder
  3. 5.1.2 Schizophrenia
  4. 5.1.3 Unipolar Depression
  5. 5.1.4 Dementia
  6. 5.1.5 Others
  7. 5.2 Global Neuroleptics Sales Volume by Application
  8. 5.2.1 Global Neuroleptics Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Neuroleptics Sales Volume by Application (2021-2032)
  10. 5.2.3 Global Neuroleptics Sales Volume Share by Application (2021-2032)
  11. 5.3 Global Neuroleptics Sales Value by Application
  12. 5.3.1 Global Neuroleptics Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Neuroleptics Sales Value by Application (2021-2032)
  14. 5.3.3 Global Neuroleptics Sales Value Share by Application (2021-2032)
6 Neuroleptics Regional Sales and Value Analysis
  1. 6.1 Global Neuroleptics Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Neuroleptics Sales by Region (2021-2032)
  3. 6.2.1 Global Neuroleptics Sales by Region: 2021-2026
  4. 6.2.2 Global Neuroleptics Sales by Region (2027-2032)
  5. 6.3 Global Neuroleptics Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Neuroleptics Sales Value by Region (2021-2032)
  7. 6.4.1 Global Neuroleptics Sales Value by Region: 2021-2026
  8. 6.4.2 Global Neuroleptics Sales Value by Region (2027-2032)
  9. 6.5 Global Neuroleptics Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Neuroleptics Sales Value (2021-2032)
  12. 6.6.2 North America Neuroleptics Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Neuroleptics Sales Value (2021-2032)
  15. 6.7.2 Europe Neuroleptics Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Neuroleptics Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Neuroleptics Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Neuroleptics Sales Value (2021-2032)
  21. 6.9.2 South America Neuroleptics Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Neuroleptics Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Neuroleptics Sales Value Share by Country, 2025 VS 2032
7 Neuroleptics Country-level Sales and Value Analysis
  1. 7.1 Global Neuroleptics Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Neuroleptics Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Neuroleptics Sales by Country (2021-2032)
  4. 7.3.1 Global Neuroleptics Sales by Country (2021-2026)
  5. 7.3.2 Global Neuroleptics Sales by Country (2027-2032)
  6. 7.4 Global Neuroleptics Sales Value by Country (2021-2032)
  7. 7.4.1 Global Neuroleptics Sales Value by Country (2021-2026)
  8. 7.4.2 Global Neuroleptics Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Neuroleptics Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Neuroleptics Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Neuroleptics Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Neuroleptics Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Neuroleptics Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Neuroleptics Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Neuroleptics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Neuroleptics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Neuroleptics Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Neuroleptics Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Neuroleptics Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Neuroleptics Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Neuroleptics Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Neuroleptics Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Neuroleptics Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Neuroleptics Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Neuroleptics Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Neuroleptics Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Neuroleptics Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Neuroleptics Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Neuroleptics Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Neuroleptics Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Neuroleptics Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Neuroleptics Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Neuroleptics Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Neuroleptics Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Neuroleptics Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Neuroleptics Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Neuroleptics Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Neuroleptics Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Neuroleptics Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Neuroleptics Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Neuroleptics Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Neuroleptics Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Neuroleptics Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Neuroleptics Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Neuroleptics Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Neuroleptics Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Neuroleptics Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Neuroleptics Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Neuroleptics Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Neuroleptics Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Neuroleptics Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Neuroleptics Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Neuroleptics Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Neuroleptics Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Neuroleptics Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Neuroleptics Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Neuroleptics Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Neuroleptics Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Neuroleptics Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Neuroleptics Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Neuroleptics Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Neuroleptics Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Neuroleptics Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Neuroleptics Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Neuroleptics Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Neuroleptics Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Neuroleptics Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Neuroleptics Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Neuroleptics Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Neuroleptics Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Neuroleptics Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Neuroleptics Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Neuroleptics Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Neuroleptics Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Neuroleptics Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Neuroleptics Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Neuroleptics Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Neuroleptics Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Neuroleptics Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Neuroleptics Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Neuroleptics Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Neuroleptics Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Neuroleptics Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Neuroleptics Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Neuroleptics Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Neuroleptics Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Neuroleptics Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Neuroleptics Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Neuroleptics Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Neuroleptics Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Neuroleptics Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Neuroleptics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Johnson & Johnson
  2. 8.1.1 Johnson & Johnson Company Information
  3. 8.1.2 Johnson & Johnson Business Overview
  4. 8.1.3 Johnson & Johnson Neuroleptics Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Johnson & Johnson Neuroleptics Product Portfolio
  6. 8.1.5 Johnson & Johnson Recent Developments
  7. 8.2 Eli Lilly
  8. 8.2.1 Eli Lilly Company Information
  9. 8.2.2 Eli Lilly Business Overview
  10. 8.2.3 Eli Lilly Neuroleptics Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Eli Lilly Neuroleptics Product Portfolio
  12. 8.2.5 Eli Lilly Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer Neuroleptics Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Neuroleptics Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 GSK
  20. 8.4.1 GSK Company Information
  21. 8.4.2 GSK Business Overview
  22. 8.4.3 GSK Neuroleptics Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 GSK Neuroleptics Product Portfolio
  24. 8.4.5 GSK Recent Developments
  25. 8.5 Bristol-Myers Squibb
  26. 8.5.1 Bristol-Myers Squibb Company Information
  27. 8.5.2 Bristol-Myers Squibb Business Overview
  28. 8.5.3 Bristol-Myers Squibb Neuroleptics Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Bristol-Myers Squibb Neuroleptics Product Portfolio
  30. 8.5.5 Bristol-Myers Squibb Recent Developments
  31. 8.6 AstraZeneca
  32. 8.6.1 AstraZeneca Company Information
  33. 8.6.2 AstraZeneca Business Overview
  34. 8.6.3 AstraZeneca Neuroleptics Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 AstraZeneca Neuroleptics Product Portfolio
  36. 8.6.5 AstraZeneca Recent Developments
  37. 8.7 Allergan
  38. 8.7.1 Allergan Company Information
  39. 8.7.2 Allergan Business Overview
  40. 8.7.3 Allergan Neuroleptics Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Allergan Neuroleptics Product Portfolio
  42. 8.7.5 Allergan Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Neuroleptics Value Chain Analysis
  2. 9.1.1 Neuroleptics Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Neuroleptics Sales Mode & Process
  6. 9.2 Neuroleptics Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Neuroleptics Distributors
  9. 9.2.3 Neuroleptics Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst